Research Article
The Clinical Features of Inflammatory Bowel Disease in Patients with Obesity
Table 1
Demographic and clinical characteristics of patients with obesity and matched controls: Crohn’s disease.
| | | Crohn’s disease (BMI > 30) | Crohn’s disease (BMI < 30) | -value |
| | No. of patients | 16 | 64 | | | Median BMI at diagnosis (range) | 31.8 (30.1–41.5) | 19.1 (14.5–29.3) | | | Male (%) | 11 (68.8) | 44 (68.8) | 1.000 | | Median age at diagnosis (range), year | 21.3 (17.9–34.8) | 21.2 (17.9–35.9) | 0.957 | | Median interval from onset to diagnosis (range), months | 9.4 (0.0–117.7) | 9.5 (0.1–108.2) | 0.995 | | Mean follow-up after diagnosis of IBD (months) | 102.1 ± 58.4 | 91.0 ± 48.6 | 0.435 | | Smoking status at diagnosis (%) | | | 0.517 | | Current smokers | 5 (31.3) | 20 (31.3) | | | Ex-smokers | 1 (6.3) | 1 (1.6) | | | Never-smokers | 10 (62.5) | 43 (67.2) | | | Disease location at diagnosis (Montreal classification) | | | 0.712 | | L1 (terminal ileum) | 5 (31.3) | 14 (21.9) | | | L2 (colon) | 1 (6.3) | 4 (6.3) | | | L3 (ileocolon) | 10 (62.5) | 46 (71.9) | | | L4 (upper GI modifier) | 4 (25.0) | 16 (25.0) | 1.000 | | Disease location, final (Montreal classification) | | | 1.000 | | L1 (terminal ileum) | 4 (25.0) | 14 (21.9) | | | L2 (colon) | 0 (0.0) | 3 (4.7) | | | L3 (ileocolon) | 12 (75.0) | 47 (73.4) | | | L4 (upper GI modifier) | 4 (25.0) | 18 (28.1) | 1.000 | | Perianal fistula | | | 0.592 | | At diagnosis | 8 (50.0) | 24 (37.5) | | | Occurrence during follow-up | 1 (6.3) | 8 (12.5) | | | Never | 7 (43.8) | 32 (50.0) | | | Disease behavior at diagnosis (Montreal classification) | | | 1.000 | | B1 (nonstricturing and nonpenetrating) | 13 (81.3) | 48 (75.0) | | | B2 (stricturing) | 1 (6.25) | 5 (7.8) | | | B3 (penetrating) | 2 (12.5) | 11 (17.2) | | | Disease behavior, final (Montreal classification) | | | 0.717 | | B1 (nonstricturing and nonpenetrating) | 9 (56.3) | 41 (64.1) | | | B2 (stricturing) | 2 (12.5) | 10 (15.6) | | | B3 (penetrating) | 5 (31.3) | 13 (20.3) | | | Medication history | | | | | Steroids | 7 (43.8) | 37 (57.8) | 0.334 | | Immunomodulators | 16 (100.0) | 57 (89.1) | 0.312 | | Anti-tumor necrosis factor therapy | 8 (50.0) | 21 (32.8) | 0.201 | | Surgical outcomes | | | | | Bowel resection | 7 (43.8) | 18 (28.1) | 0.228 |
|
|
GI, gastrointestinal, IBD, inflammatory bowel disease, UC, ulcerative colitis, and BMI, body mass index.
|
